Description of preliminary study | |||||||||
---|---|---|---|---|---|---|---|---|---|
Pilot | Feasibility | Both | Total | ||||||
n | (%) | n | (%) | n | (%) | n | (%) | ||
Number of arms | Two | 39 | 78.0 | 25 | 100.0 | 4 | 100.0 | 68 | 86.1 |
Three | 10 | 20.0 | 0 | 0.0 | 0 | 0.0 | 10 | 12.7 | |
Four | 1 | 2.0 | 0 | 0.0 | 0 | 0.0 | 1 | 1.3 | |
Type of trial | Health technology | 34 | 68.0 | 23 | 92.0 | 3 | 75.0 | 60 | 75.9 |
Drug | 16 | 32.0 | 2 | 8.0 | 1 | 25.0 | 19 | 24.1 | |
Disease area | Stroke | 4 | 8.0 | 1 | 4.0 | 0 | 0.0 | 5 | 6.3 |
Mental health | 11 | 22.0 | 6 | 24.0 | 1 | 25.0 | 18 | 22.8 | |
Oncology | 4 | 8.0 | 4 | 16.0 | 0 | 0.0 | 8 | 10.1 | |
Respiratory | 3 | 6.0 | 1 | 4.0 | 0 | 0.0 | 4 | 5.1 | |
Oral & Gastrointestinal | 3 | 6.0 | 2 | 8.0 | 0 | 0.0 | 5 | 6.3 | |
Dementias | 3 | 6.0 | 1 | 4.0 | 0 | 0.0 | 4 | 5.1 | |
Cardiovascular | 2 | 4.0 | 2 | 8.0 | 1 | 25.0 | 5 | 6.3 | |
Primary care | 5 | 10.0 | 2 | 8.0 | 0 | 0.0 | 7 | 8.9 | |
Musculoskeletal | 4 | 8.0 | 1 | 4.0 | 0 | 0.0 | 5 | 6.3 | |
Other | 11 | 22.0 | 5 | 20.0 | 2 | 50.0 | 18 | 22.8 | |
Type of end point | Dichotomous | 15 | 30.0 | 12 | 48.0 | 4 | 100.0 | 31 | 39.2 |
Continuous | 35 | 70.0 | 10 | 40.0 | 0 | 0.0 | 45 | 57.0 | |
Time-to-event | 0 | 0.0 | 1 | 4.0 | 0 | 0.0 | 1 | 1.3 | |
Other | 0 | 0.0 | 2 | 8.0 | 0 | 0.0 | 2 | 2.5 | |
Funder | Industry | 11 | 22.0 | 1 | 4.0 | 1 | 25.0 | 13 | 16.5 |
Public | 27 | 54.0 | 17 | 68.0 | 3 | 75.0 | 47 | 59.5 | |
Charity | 12 | 24.0 | 7 | 28.0 | 0 | 0.0 | 19 | 24.1 |